Further research identified a feedback loop in thyroid cancer cells, where RAF and MEK inhibition led to HER3 upregulation, ultimately reactivating the MAPK pathway and limiting the sustained effects of BRAF inhibition (53). The gene discussed is ERBB3; the disease is thyroid gland carcinoma.